Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Wednesday, February 19, 2025 2 min read
Key Takeaway: Ardelyx, Inc. announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3, 2025, in Boston. The company's management will present at the event, which attendees can access via a live webcast. Ardelyx aims to provide innovative medicinal solutions for significant health needs, and it currently has two approved products in the U.S., along with international commercialization agreements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is actively participating in a prominent healthcare conference.
  • The company has a strong mission focused on unmet medical needs.
  • Ardelyx has two commercial products that are already approved.

Full Press Release Details

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When is Ardelyx presenting at the TD Cowen Health Care Conference?

Ardelyx will present on March 3, 2025, at 9:50am ET.

Where can I access the Ardelyx presentation webcast?

The webcast can be accessed on the Events and Presentations page of Ardelyx's website.

What products does Ardelyx have approved in the U.S.?

Ardelyx has two approved products: IBSRELA® and XPHOZAH®.

Who commercializes tenapanor outside the U.S.?

Kyowa Kirin commercializes tenapanor in Japan, while Knight Therapeutics in Canada.

What is the purpose of Ardelyx's mission?

Ardelyx aims to develop innovative, first-in-class medicines to address unmet medical needs.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx tenapanor health care conference IBSRELA hyperphosphatemia
Last updated: Feb 19, 2025